Literature DB >> 23816510

Prevalence of Toxoplasma gondii infection among individuals with severe mental illness in Nigeria: a case control study.

Bawo O James1, Imafidon O Agbonile, Modupe Okolo, Ambrose O Lawani, Joyce O Omoaregba.   

Abstract

BACKGROUND: While the aetiology for most psychotic disorders is unknown, a strong association has been observed between Toxoplasma gondii infection and psychosis. The proportion of individuals with psychotic disorders who have current or past infection with toxoplasma has been varied. Reports from the African continent have however been scanty.
METHODS: A case control study of patients with a psychotic disorder presenting for the first time to a regional psychiatric facility was undertaken and compared to age and sex-matched healthy controls. In addition to socio-demographic and clinical characteristics, seroprevalence (IgG and IgM) of T. gondii was undertaken using an immunoassay test kit.
RESULTS: IgG seropositivity was significantly higher among cases (30·7% vs 17·85%, OR = 2·04, 95% CI = 1·12-3·74, P<0·02). In contrast, IgM seropositivity was significantly lower among the cases (7·14% vs 8·57%, OR = 0·82, 95% CI = 0·31-2·16, P = 0·82). Cases who were IgG seropositive to T. gondii were more likely to be older (P<0·001) and female (P<0·001). There was no statistically significant difference in terms of T. gondii infection and, eaten poorly cooked meat (0·88), and diagnostic group (P = 0·53). Though there was a trend towards exposure to cats, this failed to reach significance (P = 0·08).
CONCLUSION: T. gondii (IgG) infection is common among individuals with severe mental illness sampled and significantly higher compared to controls.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23816510      PMCID: PMC4001469          DOI: 10.1179/2047773213Y.0000000093

Source DB:  PubMed          Journal:  Pathog Glob Health        ISSN: 2047-7724            Impact factor:   2.894


  18 in total

1.  Toxoplasma gondii and other risk factors for schizophrenia: an update.

Authors:  E Fuller Torrey; John J Bartko; Robert H Yolken
Journal:  Schizophr Bull       Date:  2012-03-23       Impact factor: 9.306

2.  Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis.

Authors:  E Fuller Torrey; John J Bartko; Zhao-Rong Lun; Robert H Yolken
Journal:  Schizophr Bull       Date:  2006-11-03       Impact factor: 9.306

Review 3.  Effects of Toxoplasma gondii infection on the brain.

Authors:  Vern B Carruthers; Yasuhiro Suzuki
Journal:  Schizophr Bull       Date:  2007-02-23       Impact factor: 9.306

4.  Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii's ability to alter host behaviour.

Authors:  J P Webster; P H L Lamberton; C A Donnelly; E F Torrey
Journal:  Proc Biol Sci       Date:  2006-04-22       Impact factor: 5.349

5.  Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring.

Authors:  Alan S Brown; Catherine A Schaefer; Charles P Quesenberry; Liyan Liu; Vicki P Babulas; Ezra S Susser
Journal:  Am J Psychiatry       Date:  2005-04       Impact factor: 18.112

Review 6.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

Authors:  D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

7.  Subtypes and factors of schizophrenia in an acutely ill Nigerian sample.

Authors:  Jude U Ohaeri; David I Otote
Journal:  Psychopathology       Date:  2003 Jul-Aug       Impact factor: 1.944

8.  Post-traumatic stress disorder after childbirth in Nigerian women: prevalence and risk factors.

Authors:  A O Adewuya; Y A Ologun; O S Ibigbami
Journal:  BJOG       Date:  2006-03       Impact factor: 6.531

9.  Seroprevalence of Toxoplasma gondii in Nazaret town, Ethiopia.

Authors:  T Negash; G Tilahun; G Medhin
Journal:  East Afr J Public Health       Date:  2008-12

10.  Seroprevalence of Toxoplasma gondii infection in Kwal, a rural distriction of Plateau-Nigeria.

Authors:  C J Uneke; D D Duhlinska; B A F Ngwu; M O Njoku
Journal:  Afr J Med Med Sci       Date:  2007-06
View more
  6 in total

1.  Meta-Analysis of Anti-Toxoplasma gondii IgM Antibodies in Acute Psychosis.

Authors:  Joel M Monroe; Peter F Buckley; Brian J Miller
Journal:  Schizophr Bull       Date:  2014-11-09       Impact factor: 9.306

2.  Prevalence and Predictors of Toxoplasma gondii Infection in Psychiatric Inpatients in Fars Province, Southern Iran.

Authors:  Aref Teimouri; Othman Jamal Nassrullah; Pouya Hedayati; Mohammad Saleh Bahreini; Rasoul Alimi; Sina Mohtasebi; Amir Masoud Salemi; Qasem Asgari
Journal:  Front Psychiatry       Date:  2022-06-14       Impact factor: 5.435

3.  High seroprevalence of Toxoplasma gondii infection in inmates: A case control study in Durango City, Mexico.

Authors:  C Alvarado-Esquivel; J Hernández-Tinoco; L F Sánchez-Anguiano; A Ramos-Nevárez; S M Cerrillo-Soto; L Sáenz-Soto; O Liesenfeld
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2014-03-14

4.  Prevalence of malaria, typhoid, toxoplasmosis and rubella among febrile children in Cameroon.

Authors:  Olivia A Achonduh-Atijegbe; Kenji O Mfuh; Aristid H E Mbange; Jean P Chedjou; Diane W Taylor; Vivek R Nerurkar; Wilfred F Mbacham; Rose Leke
Journal:  BMC Infect Dis       Date:  2016-11-08       Impact factor: 3.090

5.  A Case-Control Seroprevalence Study on the Association Between Toxoplasma gondii Infection and Bipolar Disorder.

Authors:  Cosme Alvarado-Esquivel; Sergio Estrada-Martínez; Alma Rosa Pérez-Alamos
Journal:  Front Psychiatry       Date:  2019-10-25       Impact factor: 4.157

6.  Is latent Toxoplasma gondii infection associated with the occurrence of schizophrenia? A case-control study.

Authors:  Muluneh Ademe; Tadesse Kebede; Solomon Teferra; Melkam Alemayehu; Friehiwot Girma; Tamrat Abebe
Journal:  PLoS One       Date:  2022-06-23       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.